PuSH - Publication Server of Helmholtz Zentrum München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Gottschlich, A.* ; Endres, S. ; Kobold, S.

Therapeutic strategies for targeting IL-1 in cancer.

Cancers 13:477 (2021)
Publ. Version/Full Text DOI PMC
Open Access Gold
Creative Commons Lizenzvertrag
Interleukin-1 cytokines are key proinflammatory cytokines which have been implicated with differing pro- and antitumorigenic properties. Recent years have brought exciting insights and developments in IL-1-targeted therapies. Here, we present an overview of past and present research focusing on the role of IL-1 in cancer, with a special focus on clinical research and on therapeutic implications. With this, we strive to assist scientists in their future research objectives and to highlight possible directions for IL-1-targeting therapies in the coming years. Since its discovery, interleukin-1 has been extensively studied in a wide range of medical fields. Besides carrying out vital physiological functions, it has been implicated with a pivotal role in the progression and spreading of different cancer entities. During the last years, several clinical trials have been conducted, shedding light on the role of IL-1 blocking agents for the treatment of cancer. Additionally, recent developments in the field of immuno-oncology have implicated IL-1- induced signaling cascades as a major driver of severe chimeric antigen receptor T cell-associated toxicities such as cytokine release syndrome and immune effector cell-associated neurotoxicity. In this review, we summarize current clinical trials investigating the role of IL-1 blockade in cancer treatment and elaborate the proposed mechanism of these innovative treatment approaches. Additionally, we highlight cutting-edge developments utilizing IL-1 blocking agents to enhance the safety and efficacy of adoptive T cell therapy.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
6.639
1.292
4
12
Tags
Annotations
Special Publikation
Hide on homepage

Edit extra information
Edit own tags
Private
Edit own annotation
Private
Hide on publication lists
on hompage
Mark as special
publikation
Publication type Article: Journal article
Document type Review
Keywords Adoptive T Cell Therapy ; Cancer ; Car ; Chimeric Antigen Receptor T Cells ; Clinical Trials ; Il-1-blockade ; Immunotherapy; Cytokine Release Syndrome; Receptor T-cells; Multiple-myeloma; Interleukin-6 Production; Increased Risk; Lung-cancer; In-vivo; Growth; Inflammation; Anakinra
Language english
Publication Year 2021
HGF-reported in Year 2021
ISSN (print) / ISBN 2072-6694
Journal Cancers
Quellenangaben Volume: 13, Issue: 3, Pages: , Article Number: 477 Supplement: ,
Publisher MDPI
Publishing Place St Alban-anlage 66, Ch-4052 Basel, Switzerland
Reviewing status Peer reviewed
Institute(s) Unit for Clinical Pharmacology (KKG-EKLiP)
POF-Topic(s) 30203 - Molecular Targets and Therapies
Research field(s) Immune Response and Infection
PSP Element(s) G-522100-001
Grants
Marie Sklodowska-Curie Program Training Network for the Immunotherapy of Cancer - H2020 Program of the European Union
Marie Sklodowska-Curie Program Training Network for Optimizing Adoptive T Cell Therapy of Cancer - H2020 Program of the European Union
Hector foundation
International Doctoral Program i-Target: Immunotargeting of Cancer - Elite Network of Bavaria
Melanoma Research Alliance
Else Kroner-Fresenius-Stiftung
German Cancer Aid
Ernst Jung Stiftung
LMU Munich's Institutional Strategy LMUexcellent within the framework of the German Excellence Initiative
Bundesministerium fur Bildung und Forschung Project Oncoattract
European Research Council
German Research Foundation (DFG)
Fritz-Bender Foundation
Jose-Carreras Foundation
DOI 10.3390/cancers13030477
WOS ID WOS:000614990600001
Scopus ID 85099982390
PubMed ID 33530653
Erfassungsdatum 2021-02-04
[➜Report correction]